BeneluxA collaboration joint pricing negotiations fail

Eveline Van Keymeulen

The first joint pricing negotiations for a medicinal product in the context of the BeneluxA collaboration with respect to health technology assessment and pricing and reimbursement have failed. On 23 May 2017, the Belgian Minister of Health announced that the Belgian National Institute for Health and Disability Insurance (RIZIV), joined by the Dutch competent authorities, Read More

A CRISPR patent pool – one step closer to reality?

Robyn Trigg

In a press release on 10 July 2017, the Broad Institute announced that is has, with joint patent owners Harvard University, the Massachusetts Institute of Technology and the Rockefeller University, entered discussions about a potential CRISPR patent pool.  The institutions collectively submitted 22 patents (from 10 patent families) for consideration to be included in a Read More

CJEU to rule on milestone in European GMO legislation: the legal classification of mutagenesis in plant breeding

Geert Glas

With the development of new plant breeding techniques, the European plant breeding sector is tackling the world’s crucial challenge of feeding the 21st-century world. New plant breeding techniques allow for much faster and more precise results than traditional plant breeding techniques, and allow for more food to be produced with fewer inputs.  However, the novel Read More

Azanta A/S v EUIPO (T-49/16): General Court upholds opposition against EUTM application for NIMORAL covering pharmaceutical preparations for cancer patients

Tom Brazier

The Judgment of the General Court (Sixth Chamber) is worthy of consideration.  From a trade mark perspective, it considers the relative importance (or lack of importance as it transpired) of the relevant public’s level of attention in the assessment of likelihood of confusion.  From a healthcare angle, the relevant public were oncologists, radiotherapists and cancer Read More

Revised French transparency regime enters into force

Eveline Van Keymeulen

On 27 March 2017, with the publication of the new Order on the practical functioning of the transparency website www.transparence.sante.gouv.fr (the Order), the revised French transparency regime entered into force. The revised regime strengthens the transparency in relationships between Life Sciences companies and healthcare professionals. It was established by the 2016 French Healthcare Act and Read More